Summary The retinoblastoma gene product (RB) contributes to normal cell growth control. One of its functions is manifest as a block to exit from GI, which is carried out by an RB subspecies which is un-or underphosphorylated. After RB phosphorylation, a process which occurs towards the end of GI in cycling cells, the block is lifted allowing a cell to enter S. Here, we review a series of results which speak to the elements of RB structure which contribute to this activity. Included is its internal colinear protein receptor domain (i.e. the 'pocket').
The retinoblastoma gene product (RB) is a 928 aa nuclear protein which is synthesised in a wide variety of mammalian cells. The absence of a properly functioning RB allele in several cell types is linked to the appearance of a neoplastic phenotype. In the hereditary retinoblastoma syndrome, there is, among affected individuals, an enhanced susceptibility to multi-focal, invasive lesions of the retina. In these tumour cells, a functioning RB gene is absent. In both the founding zygote of these patients and within their normal somatic cells, only one operating RB allele is present. Given these findings, it seems fair to argue that RB function normally helps to protect retinal cells against the development of a transformed phenotype. RB is, therefore, the product of a tumour suppressor gene. Indeed, it is widely expressed among various mammalian cell types, and it likely plays a tumour suppressor role in both retinal and some non-retinal cells.
RB exists as a differentially phosphorylated set of polypeptide products of a single gene (Buchkovich et al., 1989; Chen et al., 1989; DeCaprio et al., 1989; Mihara et al., 1989; Xu et al., 1989; Ludlow et al., 1990; Decaprio et al., 1992) . Its phosphorylation is cell cycle-dependent, with cells containing un(der)phosphorylated protein through much of GI and phosphorylated protein through S, G2, and most of M (Buchkovich et al., 1989; Chen et al., 1989; DeCaprio et al., 1989; Mihara et al., 1989; Ludlow et al., 1990) . In cycling cells, RB phosphorylation begins toward the end of GI, and persists through S and G2 (DeCaprio et al., 1992) . Phosphorylated RB is enzymatically dephosphorylated in M, beginning at anaphase (Ludlow et al., 1990; Ludlow et al., 1992) . By the time cells are established in the next G1, it appears that they again contain largely unphosphorylated RB (Ludlow et al., 1993) .
RB forms complexes with certain transforming proteins of three different DNA tumour virus species. Adenovirus EIA, papovaviral large T antigen, and the E7 product of the transforming strains of human papilloma virus all form stable complexes with RB. All do so through the action of a short (-12 aa), colinear peptide sequence (the 'yellow block' sequence) imbedded within each protein structure (DeCaprio et al., 1988; Whyte et al., 1988; Dyson et al., 1989a; Whyte et al., 1989) . All of these 'yellow block' elements conform to a tight consensus sequence which describes them, and peptide replicas of each will bind effectively to RB, competing with each of the viral proteins in the process (Kaelin et al., 1990) .
Genetic analysis indicates that ElA, T, or E7 binding to RB contributes to the transforming function of each of these proteins. Indeed, it was further concluded that when each of them binds to RB, it down modulates or inhibits one or more aspects of the growth regulatory function of RB Correspondence: D.M. Livingston. (DeCaprio et Whyte et al., 1989; ).
Also notable is the fact that T binds only to un(der)phosphorylated RB and not to its phosphorylated forms . Since it does not lead to a redistribution of the relative abundances of these two generic RB species, it is fair to argue that the un(der)phosphorylated form of RB carries out those growth regulatory functions which T perturbs. Similarly the phosphorylated forms lack these particular functions, although it seems likely that they can perform other RB growth regulating actions. Given this, it can be argued that the timely phosphorylation of RB near the end of GI inactivates those aspects of RB growth regulatory function which T can perturb. Since T is a known mitogen capable of driving a Gl arrested cell into S and RB is a growth suppressing element (Mueller et al., 1978; Soprano et al., 1983; Huang et al., 1988) , we have suggested that un(der)phosphorylated RB normally operates, at least in part, by blocking exit from GI and that this block can be lifted by RB phosphorylation (DeCaprio et al., 1989; Ludlow et al., 1989; Ludlow et al., 1990) .
Within the RB sequence, there is a -400 aa colinear segment which, alone, can bind T, ElA, or E7 with roughly the same affinity as intact RB (Hu et al., 1990; Huang et al., 1990; Kaelin et al., 1990) . We have labelled this segment, the RB 'pocket', being a large internal protein receptor domain of the protein. Indeed, the pocket not only contacts viral transforming proteins, it also binds to a complex set of cellular proteins. Dissected away from the remainder of the RB sequence, the 'pocket' can still interact stably with both the aforementioned viral and cellular proteins . Since this domain is large and is a prominent site of naturally occurring mutations in human tumours which inactivate RB function, one obvious question is whether its function contributes to the growth suppression function of unphosphorylated RB. In this report, we will review experiments which attempt to answer this question (Qin et al., 1992) .
Results
Effects of introducing RB into the RB-1-cell line, Saos-2 Others had shown previously that introduction of RB into a number of RB-/-cell lines will arrest cell growth Bookstein et al., 1990; Takahashi et al., 1991) . In Saos-2, a line of human osteogenic sarcoma cells, we found that this phenotype was joined by the appearance of prominent cellular swelling (Qin et al., 1992) (Figure 1 ). An immediate question was whether both sets of phenotypes were tightly linked to the production of RB and, if so, whether the same sets of RB sequences were needed to effect both biological changes. We have not answered these two questions in full, but do know the following. First, when RB Br. J. Cancer (1993), 68, 264-268 V t J 1 ' . (Qin et al., 1992) .
was introduced into Saos-2 in the presence of a neoR marker, there was a dramatic reduction in G418R colony formation (Qin et al., 1992) (Figure 2) . Since no such reduction was noted in the absence of RB synthesis, this phenotype could be laid at the doorstep of RB.
The RB pocket must be intact for growth suppression in these assays When various RB mutants were tested in these assays, we found that the RB 'pocket' was essential to the appearance of 'big' cells and to the cessation of growth (Qin et al., 1992) ( Figure 2 ). This was manifest by the failure of the C706-*F mutant of RB to block colony formation and the appearance of large cells (Qin et al., 1992) (Figures 2 and 1) . Indeed, when various RB deletion mutants were studied, it became clear that both the RB pocket and much, if not all, of its C-terminal 135 aa were essential to suppressing drug-resistant colony formation (Qin et al., 1992) (Figure 4) .
What is the significance offinding that the RB pocket and its C-terminus are both essential to blocking G418 colony formation?
The RB pocket can form complexes with at least 8 or more cellular proteins in vitro , making it difficult, ab initio, to single out which, if any, of the known interactions are essential to the RB growth suppression effect. However, it is also clear that another RB binding protein, the transcription factor, E2F, can, unlike the others, be assayed functionally. Although we knew that the pocket contributed to its binding to RB, it was not clear whether the pocket was sufficient for this effect (Chittenden et al., 1991) . Thus, we measured the E2F binding activity of a series of RB mutants, much as we did earlier for their growth suppression effect (Qin et al., 1992) (Figure 3 ). In all of this, the main question was whether there was linkage between the ability of RB to interact with E2F and its ability to induce cell cycle blockade in Saos-2. . RB ( | ' : . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Figure 4 , there was a neat correlation between the ability of RB to sustain a GI block in Saos-2 and to form a stable complex with E2F. The latter was determined in a series of in vitro gel shift assays, in which various GST-RB fusion proteins were mixed with crude E2F, and the appropriate RB-E2F supershift complex was sought. The data clearly show that both the pocket and the C-terminus of RB are essential to complex formation, as they are to growth suppression. This didn't prove that complex formation with E2F is essential to growth suppression. However, it opened this possibility to futher investigation.
Discussion
These data show that when RB was introduced into at least one line of cells which lack any RB function, a distinct set of biological effects was observed. In Saos-2 cells, RB synthesis is followed by two major events. The cells swell, but remain attached to the dish. They are also unable to grow, in keeping with the earlier findings of others Goodrich et al., 1991) , who went on to show that the cell cycle block was in GI. Our aim was to learn whether the RB pocket is a functional domain in vivo and contributes to the aforementioned growth suppression effect.
The data show that it is, for the introduction of a single amino acid substitution in the pocket, which otherwise inactivates its protein binding function, also eliminated the ability of RB to suppress growth. The surprise in all of this was the demonstration that the C-terminal segment of the protein was also important to the growth suppression function. Indeed, all assays of protein binding had suggested that the -400 residue minimal 'pocket' domain was sufficient to bind all of the 35S-cellular protein bands identified in cell free assays . This implied that there was more to the protein binding function of RB than the action of its minimal pocket domain and that this more complex action could in theory, be part of the answer to how RB suppresses cell growth in G1.
The results on E2F binding open the possibility that an interaction of the RB pocket and C-terminus with this protein(s) contributes to the RB growth suppression function.
Clearly, a correlation of this sort is not proof of this possibility. However, there is good reason to pursue it further. E2F is known to play a role in the activation of a number of genes whose products do the work of the cell cycle-such as DHFR, c-myc, and cdc2 and others (Thalmeier et al., 1989; Hiebert et al., 1991; Dalton, 1992 : Hamel et al., 1992 Kim et al., 1992; Means et al., 1992; Moberg et al., 1992) . A number of these genes, when activated, contribute to exit from GI and passage through S. This being the case, one wonders whether the interaction of unphosphorylated RB with E2F contributes to the silencing of one or more of these genes. Unphosphorylated RB is endowed, we believe, with the GI exit blocking activity of RB, and others have shown that it can suppress the action of E2F in vivo. Whether this is a direct or an indirect effect or both is not known, although there is reason to suspect that direct complex formation exists and may contribute to the modulation of E2F action (Hamel et al., 1992; Hiebert et al., 1992) .
Whatever the outcome of the next generation of experiments, it seems clear that RB has a powerful ability to modulate cell growth, that its pocket domain contributes to this action likely through forming specific complexes with other cellular proteins, and that the elimination of this function of RB can contribute to the neoplastic phenotype of common human tumour cells. The challenge now is to decipher which RB interactions contribute to its growth modulating function, in which ways E2F complex formation is linked to RB growth controlling function, and how RB interactions with a variety of other protein targets are translated into key growth controlling signals.
Once clearly understood in biochemical terms, it may be possible to use this and information like it to design rational strategies for cancer drug development. With the availability of the right cloned proteins in wild type and appropriately mutant forms, one should, in principle, be able to design the rapid screens necessary to detect small molecule compounds which can selectively perturb individual protein targets involved in growth control in common human tumour cells. The ideal compounds in this case would be those which can only affect growth of cells which have sustained functionaltering mutations in one or more key growth controlling loci such as RB.
